Completed PHASE1 INTERVENTIONAL 1-arm NCT04231747

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Sponsor: Juno Therapeutics, a Subsidiary of Celgene

Conditions Agressive Lymphoma Diffuse-large B-cell Lymphoma (DLBCL) Lymphoma Non-Hodgkin

Interventions CC-97540

Updated 19 times since 2020 Last updated: May 17, 2024 Started: May 21, 2020 Primary completion: Feb 1, 2024 Completion: Feb 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Agressive Lymphoma and Diffuse-large B-cell Lymphoma (DLBCL), this trial is completed. The trial is conducted by Juno Therapeutics, a Subsidiary of Celgene and has accumulated 19 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

19 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Aug 2023 — Jun 2024 [monthly]

Active Not Recruiting PHASE1
Apr 2023 — Aug 2023 [monthly]

Active Not Recruiting PHASE1

▶ Show 14 earlier versions

Nov 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1
Nov 2021 — Sep 2022 [monthly]

Recruiting PHASE1
Sep 2021 — Nov 2021 [monthly]

Recruiting PHASE1
May 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Apr 2021 — May 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE1
Oct 2020 — Nov 2020 [monthly]

Recruiting PHASE1
Jul 2020 — Oct 2020 [monthly]

Recruiting PHASE1
Jun 2020 — Jul 2020 [monthly]

Recruiting PHASE1
Apr 2020 — Jun 2020 [monthly]

Recruiting PHASE1
Feb 2020 — Apr 2020 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Juno Therapeutics, a Subsidiary of Celgene

Data source: Juno Therapeutics, a Subsidiary of Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Boston, United States , Calgary, Canada , Charlotte, United States , Hackensack, United States , Hamilton, Canada , New York, United States , Omaha, United States , Portland, United States and 2 more locations